Clinical Trial

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Esophageal Cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-19; most recent amendment 2025-01-02.
Status change: Not Yet Recruiting → Recruiting 2024-07-09
Trial Details
NCT Number NCT06474468
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced or Metastatic Esophageal Cancer
Enrollment 148 participants
Start Date 2024-06-20
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-01-03